What PNC-27 Is
PNC-27 is a 32-residue peptide engineered to target cancer cells (PMID 35625682). It consists of two main parts: an HDM-2 binding domain, derived from residues 12-26 of the p53 protein, and a cell-penetrating peptide (CPP) leader sequence (PMID 35625682, PMID 20080680). The HDM-2 binding domain is critical for its action (PMID 28667027, PMID 20080680). PNC-27 acts as the whole peptide, not in fragments, to induce cancer cell membrane lysis (PMID 20182728).
How PNC-27 Is Thought to Work
PNC-27 is believed to kill cancer cells by interacting with membrane-bound HDM-2, a protein found in the membranes of various cancer cells but not in normal (untransformed) cells (PMID 40750238, PMID 20080680). In cells, PNC-27 binds to the p53 binding site (residues 1-109) of HDM-2 (PMID 38802154). This binding leads to the formation of transmembrane pores, causing the extrusion of intracellular contents and subsequent cell lysis and necrosis (PMID 38802154, PMID 35625682, PMID 20080680, PMID 32878773). Immuno-scanning electron microscopy in cancer cells suggests PNC-27 forms approximately 1:1 complexes with HDM-2 in ring-shaped structures within these pores (PMID 35625682). Additionally, in cancer cells, PNC-27 has been observed to enter the cell and bind to mitochondrial membranes, leading to mitochondrial disruption (PMID 38802154).
Laboratory and Animal Studies Report
In cell studies, PNC-27 selectively kills various cancer cell lines, including human pancreatic carcinoma cells (MIA-PaCa-2), breast cancer cells (MCF-7), ovarian cancer cells (ID8), cervical cancer cells (HTB-35), colon cancer cells (HT-29, CT-26), and leukemia cell lines (U937, OCI-AML3, HL60), in a dose-dependent manner (PMID 38802154, PMID 28667027, PMID 20182728, PMID 40750238, PMID 36311203, PMID 32878773). Importantly, it does not affect normal or untransformed cells such as untransformed fibroblasts, untransformed breast epithelial cells (MCF-10-2A), untransformed cervical cells (PCS-480), or normal hematopoietic cells (PMID 35625682, PMID 20080680, PMID 20182728, PMID 40750238, PMID 32878773). Expression of membrane-bound HDM-2 in cancer cells, but not normal cells, is consistently observed as a key factor for PNC-27's selectivity (PMID 40750238, PMID 20080680). Blocking HDM-2 in cells inhibits PNC-27's killing effect (PMID 28667027). In an animal model of ovarian cancer (ID8 cells in mice), the addition of PNC-27 to weekly paclitaxel administration significantly reduced tumor growth, demonstrating synergy (PMID 28667027).
Potential Applications of PNC-27 Conjugates
In cell studies, PNC-27 has been evaluated for use in targeted diagnostic applications. PNC-27 conjugated to polyethyleneimine (PEI)-superparamagnetic iron oxide nanoparticles (SPIONs) showed higher binding and uptake in cancer cell lines (HT-29 and CT-26) compared to normal cells (NIH-3t3) (PMID 36311203). This suggests the potential for PNC-27 to act as a double targeting agent for early cancer diagnosis by guiding nanoparticles to HDM-2 expressing cancer cells (PMID 36311203).
